Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MORPHEUS-BREAST CANCER: A Study of Multiple Treatment Combinations in Patients With Breast Cancer
NCT04802759Phase 2Recruiting
- Sponsor
- Roche
- Start
- Jun 2021
- Primary completion
- May 2029
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of giredestrant in breast cancer (16 cohorts), sponsored by Roche. Primary endpoints: Objective Response Rate up to 6 years and Adverse Events up to 6 years. Started Jun 2021; status: recruiting.
02
Drugs
giredestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04802759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04802759.